Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 176, Issue 6, Pages 867-882Publisher
WILEY
DOI: 10.1111/bjh.14474
Keywords
acute lymphoblastic leukaemia; genomics; paediatrics; precision medicine; therapy
Categories
Funding
- Gilead Sciences
Ask authors/readers for more resources
Major advances in genetic and epigenetic profiling of acute lymphoblastic leukaemia (ALL) have enhanced the understanding of key biological subsets of de novo and relapsed ALL, which has led to improved risk stratification of patients. These achievements have further defined critical leukaemia-associated pathways and somatic alterations that may be preferentially sensitive to treatment with kinase inhibitors, epigenetic therapy or other novel agents. Therapeutic success in childhood ALL currently relies upon refined risk stratification of patients based on (i) underlying biological and clinical characteristics, and (ii) depth of initial treatment response with appropriate modulation of chemotherapy intensity. This review describes the current mutational landscape of childhood ALL and discusses opportunities for substantial improvements in survival with implementation of molecularly targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available